Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Thursday, 21'st Aug 2025
WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 202
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
03:53pm, Wednesday, 20'th Aug 2025
Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 re
Top 3D Printing Stocks for Higher Returns and Portfolio Growth
01:31pm, Tuesday, 19'th Aug 2025
3D Printing is reshaping industries with faster production and lower costs, drawing investor interest. Stocks like GE, PTC, CRS, PRLB and DDD offer strong growth potential.
Top AI Stocks to Add to Your Portfolio for Healthy Returns
12:41pm, Tuesday, 19'th Aug 2025
Here, we have picked three AI stocks, PTC, AVGO and MSFT, which are well-poised to benefit from AI's growing use and ability to solve complex problems.
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
11:20am, Tuesday, 19'th Aug 2025
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s PTCT New Drug Application (NDA) for vatiquinone for Friedreich's at
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug
08:06am, Tuesday, 19'th Aug 2025
The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday,
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
08:00am, Tuesday, 19'th Aug 2025
WARREN, N.J. , Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related
Best Growth Stocks to Buy for August 18th
10:25am, Monday, 18'th Aug 2025
ZWS, SHG and PTC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 18, 2025.
PTC Appoints Jon Stevenson as Executive Vice President, Chief Product Officer
08:30am, Monday, 11'th Aug 2025
BOSTON , Aug. 11, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Jon Stevenson as Executive Vice President, Chief Product Officer. Stevenson will be responsible for the
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 07'th Aug 2025
– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J. , Aug. 7, 2
PTC Inc. (PTC) Upgraded to Strong Buy: Here's Why
01:01pm, Wednesday, 06'th Aug 2025
PTC Inc. (PTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PTC Will Participate in Upcoming Investor Conferences
07:00am, Wednesday, 06'th Aug 2025
BOSTON , Aug. 6, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it will participate in the following conferences. What: Oppenheimer 28th Annual Technology, Internet & Communications Virtu
Looking for a Growth Stock? 3 Reasons Why PTC Inc. (PTC) is a Solid Choice
01:46pm, Tuesday, 05'th Aug 2025
PTC Inc. (PTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Can PTC Inc. (PTC) Run Higher on Rising Earnings Estimates?
01:21pm, Tuesday, 05'th Aug 2025
PTC Inc. (PTC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why PTC Inc. (PTC) is a Strong Growth Stock
10:46am, Tuesday, 05'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
